{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Will be summarized by treatment arm and compared using Wilcoxon rank sum tests","groups":[{"description":"Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nTbo-filgrastim: Given subcutaneously\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG000","title":"Group I (auto HSCT tbo-filgrastim)"},{"description":"Patients undergo auto Hematopoietic Cell Transplantation (HSCT).\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG001","title":"Group II (auto HSCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This data set was not reported. Upon further inspection into the subject data, there were few infections and most of the fevers were from neutropenia. No qualifying infections or fevers were reported to fit this specific criteria. Therefore, the numbers are presented as zero for both arms. Specific adverse event reporting data can be found in more detail in the AE/SAE section of this record.","reportingStatus":"POSTED","timeFrame":"Up to 60 days","title":"Median Number of Febrile Days During the Auto HSCT Inpatient Stay","type":"SECONDARY","unitOfMeasure":"Participants"}